NewsBenzingaTeva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Teva Pharmaceutical Indus Raises FY2026 Adj EPS Guidance from $1.91-$2.11 to $1.92-$2.11 vs $1.98 Est; Raises FY2026 Sales Guidance from $16.500B-$16.850B to $16.700B-$17.000B vs $16.651B Est Benzinga 2026.11.03 12:08 (GMT+0) Open on Benzinga Other news Leerink Partners Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $35 What's Going on With AST SpaceMobile Stock on Monday? Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years Stock of the Day: Is Pepsi About to Break Out? Intel Extends Slide as Nvidia Trims Stake 25%, Shareholder Suit Adds Pressure HC Wainwright & Co. Maintains Buy on Soluna Holdings, Lowers Price Target to $3
Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 Years